AV Lopinavir
(Unterschied zwischen Versionen)
| Zeile 1: | Zeile 1: | ||
{{tp|p=32271456|t=2020. Clinical efficacy of lopinavir/ritonavir in the treatment of Coronavirus disease 2019 |pdf=|usr=}} | {{tp|p=32271456|t=2020. Clinical efficacy of lopinavir/ritonavir in the treatment of Coronavirus disease 2019 |pdf=|usr=}} | ||
{{tp|p=32362644|t=2020. Lopinavir/ritonavir combination therapy amongst symptomatic coronavirus disease 2019 patients in India: Protocol for restricted public health emergency use |pdf=|usr=}} | {{tp|p=32362644|t=2020. Lopinavir/ritonavir combination therapy amongst symptomatic coronavirus disease 2019 patients in India: Protocol for restricted public health emergency use |pdf=|usr=}} | ||
| + | {{tp|p=32173576|t=2020. Patients of COVID-19 may benefit from sustained Lopinavir-combined regimen and the increase of Eosinophil may predict the outcome of COVID-19 progression |pdf=|usr=}} | ||
Version vom 18. Juni 2020, 10:36 Uhr
32271456 2020. Clinical efficacy of lopinavir/ritonavir in the treatment of Coronavirus disease 2019
32362644 2020. Lopinavir/ritonavir combination therapy amongst symptomatic coronavirus disease 2019 patients in India: Protocol for restricted public health emergency use
32173576 2020. Patients of COVID-19 may benefit from sustained Lopinavir-combined regimen and the increase of Eosinophil may predict the outcome of COVID-19 progression
